scholarly journals Plasma Calcitonin Gene-Related Peptide: A Potential Biomarker for Diagnosis and Therapeutic Responses in Pediatric Migraine

2019 ◽  
Vol 10 ◽  
Author(s):  
Pi-Chuan Fan ◽  
Ping-Hung Kuo ◽  
Ming Tatt Lee ◽  
Shu-Hui Chang ◽  
Lih-Chu Chiou
Keyword(s):  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Pediatric Migraine ◽  
Potential Biomarker ◽  
Calcitonin Gene ◽  
Therapeutic Responses

scholarly journals Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: A case series

2020 ◽  
Vol 29 (3) ◽  
pp. 212-214
Author(s):  
Yi Jing Zhao ◽  
King-Hee Ho ◽  
Pei Shieen Wong
Keyword(s):  
Monoclonal Antibody ◽  
Case Series ◽  
Calcitonin Gene Related Peptide ◽  
New Class ◽  
Related Peptide ◽  
Pediatric Migraine ◽  
Calcitonin Gene ◽  
Patient Reported ◽  
Adolescent Patients ◽  
Favorable Safety

Management of migraine in adolescents poses a great challenge, as many of the approved pharmacological migraine preventive agents have age restrictions. Following favorable safety and efficacy reports of the new class agent calcitonin gene-related peptide (CGRP) monoclonal antibody for use in migraine prevention, there is growing interest in its application in pediatric migraine. We present here a case series detailing our experience of using erenumab, a CGRP monoclonal antibody, in six adolescent patients. Two patients had a reduction of at least 50% in the mean number of monthly migraine days, one patient reported subjective improvement, while three patients did not respond to the first dose of erenumab and discontinued treatment. One patient reported constipation associated with erenumab use. We speculate that CGRP monoclonal antibody could potentially be a viable option in adolescent patients with migraine. Further evidences that support efficacy and safety of erenumab in this group is needed.

Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods

Cephalalgia ◽  
2020 ◽  
pp. 033310242095758
Author(s):  
Fatma Hanci ◽  
Yasemin Baranoglu Kilinc ◽  
Erkan Kilinc ◽  
Sevim Turay ◽  
Mustafa Dilek ◽  
...  
Keyword(s):  
Substance P ◽  
Vasoactive Intestinal Peptide ◽  
Plasma Levels ◽  
Migraine Without Aura ◽  
Pediatric Patients ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Pediatric Migraine ◽  
Calcitonin Gene ◽  
Significant Difference

Background Increasing evidence suggests that vasoactive neuropeptides such as pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide are involved in the pathophysiology of migraine in adults, but their role in pediatric migraineurs remains unclear. We prospectively investigated plasma levels of these vasoactive neuropeptides in pediatric migraine patients without aura and compared the results with those of age-matched healthy controls. Methods Thirty-eight children aged 6–18 years with migraine without aura and 20 age-matched control subjects were included in the study. Neuropeptides in plasma samples from the controls, and in either the ictal or interictal periods in pediatric migraine without aura, were measured using ELISA. Results PACAP-38 and vasoactive intestinal peptide levels in both ictal and interictal plasma were higher in the patients with pediatric migraine without aura than in the controls ( p < 0.001), although calcitonin gene-related peptide and substance P levels remained unchanged. Otherwise, no significant difference was determined between ictal and interictal periods in terms of all neuropeptide levels. Conclusions This study demonstrates increased plasma PACAP-38 and vasoactive intestinal peptide levels, but not calcitonin gene-related peptide and substance P levels, in pediatric patients with migraine during both attack and attack-free periods. The study findings suggest that PACAP-38 and vasoactive intestinal peptide may be implicated in the pathophysiology of migraine, particularly in pediatric migraineurs.

Plasma Calcitonin Gene-Related Peptide in Diagnosing and Predicting Paediatric Migraine

Cephalalgia ◽  
2009 ◽  
Vol 29 (8) ◽  
pp. 883-890 ◽  
Author(s):  
P-C Fan ◽  
P-H Kuo ◽  
S-H Chang ◽  
W-T Lee ◽  
R-M Wu ◽  
...  
Keyword(s):  
Migraine Headache ◽  
Paired Comparison ◽  
Calcitonin Gene Related Peptide ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Samples ◽  
Related Peptide ◽  
Pediatric Migraine ◽  
Calcitonin Gene ◽  
Headache Patients

To investigate the role of plasma calcitonin gene-related peptide (CGRP) in paediatric migraine, we prospectively collected 134 blood samples during or between attacks from 66 migraine, 33 non-migraine headache (non-migraine) and 22 non-headache patients, aged 4–18 years. Plasma CGRP concentrations were measured by enzyme-linked immunosorbent assay and disability by Pediatric MIgraine Disability ASsessment (PedMIDAS) questionnaire. Migraineurs had higher plasma CGRP levels than non-migraine patients ( P = 0.007). The attack level was higher than the non-attack level in migraine ( P = 0.036), but not in non-migraine, patients. This was also revealed in paired comparison ( n = 9, P = 0.015 vs. n = 4, P = 0.47). Using a threshold of 55.1 pg/ml, the sensitivity of the attack level in predicting migraine was 0.81, and specificity 0.75. The PedMIDAS score tended to be higher in the high CGRP (> 200 pg/ml, n = 7) group than in the low (< 200 pg/ml, n = 33) group (26.07 vs. 19.32, P = 0.16) using Mann–Whitney test. Plasma CGRP is useful for diagnosis in paediatric migraine.

Monoklonale Antikörper gegen CGRP oder den CGRP-Rezeptor in der Migräneprophylaxe

2020 ◽  
Vol 39 (07/08) ◽  
pp. 490-494
Author(s):  
Borries Kukowski
Keyword(s):  
Monoklonale Antikörper ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene

ZUSAMMENFASSUNGDie Charakterisierung von calcitonin gene-related peptide (CGRP) als Schlüsselmolekül in der Pathophysiologie der Migräne hat nicht nur unser Verständnis der Erkrankung, sondern auch die Entwicklung neuer Therapien vorangetrieben. Seit kurzem steht mit den monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor eine spezifische und hoch selektive Option für die medikamentöse Prophylaxe der episodischen und chronischen Migräne zur Verfügung, die in zahlreichen klinischen Studien ihre Überlegenheit gegenüber Placebo belegt hat. Hier werden Erfahrungen aus dem praktischen Behandlungsalltag zur kurz- und mittelfristigen Wirksamkeit und Verträglichkeit mitgeteilt und weitere Aspekte wie Therapiewechsel bei Non-Response, Verlauf nach Therapieende und die Frage des Wirkungsortes unter Einbeziehung bereits publizierter Daten angesprochen.

Sign in / Sign up

Export Citation Format

Share Document